- Methodology article
- Open Access
Estimation of tumor heterogeneity using CGH array data
- Kai Wang^{1, 2},
- Jian Li^{1},
- Shengting Li^{1},
- Lars Bolund^{1} and
- Carsten Wiuf^{2}Email author
https://doi.org/10.1186/1471-2105-10-12
© Wang et al; licensee BioMed Central Ltd. 2009
- Received: 30 July 2008
- Accepted: 9 January 2009
- Published: 9 January 2009
Abstract
Background
Array-based comparative genomic hybridization (CGH) is a commonly-used approach to detect DNA copy number variation in whole genome-wide screens. Several statistical methods have been proposed to define genomic segments with different copy numbers in cancer tumors. However, most tumors are heterogeneous and show variation in DNA copy numbers across tumor cells. The challenge is to reveal the copy number profiles of the subpopulations in a tumor and to estimate the percentage of each subpopulation.
Results
We describe a relation between experimental data and exact DNA copy number and develop a statistical method to reveal the heterogeneity of tumors containing a mixture of different-stage cells. Furthermore, we validate the method on simulated data and apply the method to 29 pairs of breast primary tumors and their matched lymph node metastases.
Conclusion
We demonstrate a new method for CGH array analysis that allows a tumor sample to be classified according to its heterogeneity. The method gives an interpretable series of copy number profiles, one for each major subpopulation in a tumor. The profiles facilitate identification of copy number alterations in cancer development.
Keywords
- Bacterial Artificial Chromosome
- Comparative Genomic Hybridization
- Simulated Sample
- Comparative Genomic Hybridization Array
- Wellcome Trust Sanger Institute
Background
Heterogeneity is an important characteristic of most cancers. It manifests itself in various different ways, for example as heterogeneity in gene expression, protein abundance and/or genomic DNA copy number [1–3]. In this paper we focus exclusively on heterogeneity in genomic DNA copy number. Genomic DNA copy number variation in a tumor reflects concomitant or successive development of various foci and indicates that malignant transformation of cells is a dynamic evolutionary process. Numerous studies have demonstrated that the development of tumors involves accumulation of various genetic alterations [4–8]. Comparative genomic hybridization (CGH), matrix-based BAC/oligo array CGH, or oligonucleotide-based arrays are techniques that frequently are applied to elucidate intertumor heterogeneity across cancers, patients or stages; the genomic profile of a tumor is presented at a fixed time point and averaged across different cells in the tumor.
In contrast, intratumor heterogeneity is rarely reported [9]. Laser-capture micro-dissection is a powerful tool to select few phenotypically homogeneous tumor cells, and thus a way circumvent the problem of averaging across many potentially inhomogeneous tumor cells. Methods for whole genome amplification enable researchers to obtain sufficient DNA for CGH analysis even from few cells [10]. In this way the genomic profile of a small (homogeneous) region in the tumor can be studied, whereas the heterogeneity of the tumor might be elucidated by investigating several different regions across the tumor. Naturally, the latter is time-consuming and labor intensive, and to our knowledge, has not been reported.
With the above in mind, we have developed a statistical method to study tumor heterogeneity. It takes CGH array data from individual tumors as input; one tumor sample is represented by one array and contains DNA from a potentially heterogeneous cell population. Our method estimates the number of dominant tumor subpopulations, the percentages of the subpopulations in the sample, and the copy number profiles of the dominant subpopulations. Also, the method estimates the percentage of normal cells. Normal cells are diploid (two copies of all genomic DNA) and typically consist of nonmalignant epithelium, fibroblast and/or penetrated lymphocytes. To validate the method we have simulated data according to a model derived from real CGH data. Additionally, we have mixed some real tumor samples to obtain samples with partially known profiles. Subsequently, we applied our method to 29 paired primary and lymph node metastasis breast cancer samples.
Our method can be considered a classifier in the sense that it assigns a number of subpopulations to a given tumor sample. Alternatively the method might be considered as a model selection procedure over an extensive number of models: We seek the model that explains the data best, optimizing over the number of subpopulations and the copy number profile for each subpopulation.
Results and discussion
Calibration experiment
A series of calibration experiments were conducted to test the array CGH platform in our laboratory. The majority of samples were from normal males and females (diploid samples), but some samples were from patients with genomic abnormalities, e.g. trisomies and monosomies. Importantly, all these samples are assumed to be homogeneous, i.e. all cells in a sample have the same copy number alteration(s). We fit a linear model to describe the relationship between log-copy number and log-intensity; as described in Methods (The copy number model). The parameters of the linear model, y = αx + β, are estimated to $\widehat{\alpha}$ = 0.6049, 95% CI: (0.5542,0.6556), and $\widehat{\beta}$ = -0.039, 95% CI (-0.085,0.0067), respectively. The observed and fitted values show high correlation; Pearson's regression coefficient R^{2} is greater than 0.98. The observed values and the regression line are shown [see Additional file 1].
Heterogeneity in real tumors
We applied the procedure described in Methods (Classification of samples) to estimate the level of genomic heterogeneity in 29 pairs of primary tumor and lymph node metastasis.
The method allows us to estimate the number of dominant subpopulations, the copy number profile and the percentage of cells in each subpopulation. Our method assumes a model of sequential tumor evolution where each subpopulation is evolved from the previous population by introducing new aberrations, or by making aberrations in the previous population more extreme, i.e. by increasing copy numbers or decreasing copy numbers, see Methods (Mixture modeling of tumor samples) for details.
Subpopulation summary of the 29 pairs of primary and metastasis samples
# | P _{1} | P _{2} | P _{3} | AI _{1} | AI _{2} | AI _{3} | Total | Pure | |
---|---|---|---|---|---|---|---|---|---|
T-2 | 15 | 25.3 (8.8) | - | - | 1.13 (0.76) | - | - | 0.25 (0.13) | 1.13 (0.76) |
T-3 | 13 | 33.4 (9.4) | 14.2 (5.1) | - | 0.34 (0.13) | 1.18 (0.26) | - | 0.28 (0.10) | 0.59 (0.20) |
T-4 | 1 | 23 (-) | 34 (-) | 8 (-) | 0.25 (-) | 0.53 (-) | 1.40 (-) | 0.35 (-) | 0.54 (-) |
M-2 | 16 | 24.8 (8.3) | - | - | 1.07 (1.00) | - | - | 0.21 (0.11) | 1.07 (1.00) |
M-3 | 10 | 32.5 (8.7) | 15.1 (6.1) | - | 0.45 (0.23) | 1.33 (0.41) | - | 0.33 (0.12) | 0.71 (0.30) |
M-4 | 3 | 16.7 (3.1) | 31 (6) | 8.7 (2.1) | 0.18 (0.04) | 0.48 (0.11) | 1.33 (0.17) | 0.29 (0.05) | 0.52 (0.09) |
where m_{ i }is the number of clones in segment i, C_{ ik }the copy number of segment i in subpopulation k, and |x| denotes the absolute value of x. Here we assume clones are uniformly spaced across the genome; if this is not the case the contribution from each clone can be weighted by its distance to neighbor clones. The estimated subpopulations are named P0, P1, P2, ..., and ordered according to increasing AI. P0 consists of normal cells only and has AI_{0} = 0.
("Pure" in Table 1) where p_{ k }denotes the percentage of subpopulation k, is decreasing with the number of subpopulations. This is re ecting that the percentage of the most complex subpopulation is generally not very high, whereas the percentage of the least complex is relatively much higher.
Primary tumor vs. metastasis
Metastasis | |||
---|---|---|---|
Primary | 2 | 3 | 4 |
2 | 9 | 4 | 2 |
3 | 7 | 5 | 1 |
4 | 0 | 1 | 0 |
The average percentage of the normal cell subpopulation in a tumor is around 60%, which is higher than we expected. According to the pathologists involved in removing the tumors by surgery, the samples contain at least 70% malignant cells. However, this percentage is judged by eye and represents how big a fraction of the tumor that appears to consist of normal cells. This is likely to be an overestimate because malignant cells generally are bigger than normal cells [11]. Also, some normal cells are typically removed before the samples are subjected to array analysis.
Simulation results
Prediction accuracy for simulated samples
Simulated | Predicted as | Correct | |||
---|---|---|---|---|---|
Real | 2 | 3 | 4 | (in %) | |
2 | 2 | 115 | 9 | 0 | 0.93 |
3 | 61 | 59 | 4 | 0.48 | |
4 | 57 | 48 | 19 | 0.15 | |
3 | 2 | 80 | 11 | 1 | 0.87 |
3 | 8 | 78 | 6 | 0.85 | |
4 | 6 | 60 | 26 | 0.28 | |
4 | 2 | 15 | 1 | 0 | 0.94 |
3 | 0 | 13 | 3 | 0.81 | |
4 | 0 | 1 | 15 | 0.94 |
We learn several things from the simulations (Table 3). Generally, it is possible to predict the number of subpopulations under the chosen simulation model. However, samples with 3 or 4 similar subpopulations (Table 3: Real = 2, Simulated = 3 or 4) are difficult to predict correctly (48% and 15%, respectively), whereas samples with few less similar subpopulations are much easier to predict; in Table 3 simulated samples with 2 subpopulations achieve a prediction accuracy above 87%.
Accuracy of copy numbers and percentages
#Subpopulations | |||
---|---|---|---|
2 | 3 | 4 | |
A (in %) | 2.05 (2.26) | 2.76 (2.50) | 4.78 (4.01) |
B (in %) | 89.5 (13.6) | 82.8 (10.0) | 80.5 (9.0) |
Robustness of the method
3 subpopulations | 4 subpopulations | |||||
---|---|---|---|---|---|---|
λ | 1 | 0.5 | 0.25 | 1 | 0.5 | 0.25 |
Correct | 27 | 27 | 33 | 27 | 21 | 28 |
Incorrect | 19 | 19 | 13 | 13 | 19 | 12 |
A (in %) | 4.74 (4.68) | 4.15 (3.62) | 3.52 (3.70) | 7.70 (7.95) | 5.43 (4.23) | 5.59 (5.03) |
B (in %) | 5.37 (6.89) | 5.59 (6.19) | 5.43 (7.13) | 7.43 (9.64) | 5.65 (5.35) | 6.93 (6.98) |
Segments (in %) | 37.0 | 24.4 | 11.5 | 65.1 | 45.1 | 25.6 |
Validation experiment
Validation experiment
Estimated based on (X = S1, S2) | ||||
---|---|---|---|---|
Experiment | X | X with 15% | X with 30% | |
S1 | 76,24 | - | 79,21 | 77,23 |
S1 with 15% | 82,18 | 80,20 | - | 81,19 |
S1 with 30% | 84,16 | 83,17 | 85,15 | - |
S1 | 60,29,11 | - | 72,20,8 | 70,21,9 |
S1 with 15% | 76,17,7 | 66,25,9 | - | 75,18,7 |
S1 with 30% | 79,15,6 | 72,20,8 | 80,14,6 | - |
S2 | 62,24,14 | - | 49,33,18 | 50,31,19 |
S2 with 15% | 57,28,15 | 68,20,12 | - | 57,27,16 |
S2 with 30% | 65,22,13 | 73,17,10 | 65,23,12 | - |
Table 6 shows that the predictions generally are in accordance with our expectations. All discrepancies between experimental and estimated percentages fall within the error bounds reported in Table 4. However, one of the tumor samples is best explained by three subpopulations (S1 in Table 6), whereas the two mixed samples ("S1 with 15%" and "S1 with 30%") are best explained by two subpopulations. By adding normal cells the signal from aberrant clones become diluted and it becomes more difficult to distinguish different abnormal subpopulations.
Conclusion
Tumor heterogeneity is an important aspect of tumor evolution and progression. However, this aspect has, to the best of our knowledge, largely been ignored in analysis of CGH and SNP array data [12, 13]. In Refs. [12, 13], a fraction of the tumor is assumed to contain normal cells which weaken the signal from the aberrated cells. Only Ref. [13] estimates the fraction of normal cells directly, but we cannot compare this method to ours since it is developed to SNP array data. The method described in Ref. [12] does not output the frequency of normal cells. We have introduced a novel algorithm to estimate tumor heterogeneity and evaluated its performance on simulated and real tumor data. The method adds to our understanding of the genomic aberration profile, the quantification of genomic instability in the tumor, and the heterogeneity of the tumor.
One of the main difficulties of developing quantitative methods for array CGH data is the lack of knowledge about how tumors evolve and differentiate. Better and more accurate models could be developed if more were known about tumor evolution. Therefore, it might be difficult to make decisions on a strict mathematical basis only, because the underlying hypotheses might be difficult test or validate with current data sets. The appropriateness of the novel methodology can only be evaluated in a long run in which the conclusions demonstrate utility for improving biological understanding and clinical decisions. Our approach is one possible algorithm to interpret the biology of the tumor genomic profile.
In CGH array analysis copy number changes are measured relatively to a reference level. Generally, the reference level is not known and the median (or mean) log-intensity is typically assumed to correspond to two copies; loss and amplifications are then measured relatively to the median log-intensity level. Our method makes the same assumption. This implies that a tumor sample consisting of e.g. two subpopulations, one diploid and one n-ploid, would be identified as purely diploid. Each clone will have a log-intensity value that reflects the mixture of the two subpopulations and will, erroneously, be equated with two copies. However, if the two subpopulations are not euploid, our method might be able to disentangle the two subpopulations. This situation is not unlike traditional CGH array analysis where the tumor sample will be identified as one homogeneous population. Only if additional information is available, e.g. from karyotyping, can the reference level be properly adjusted.
We anticipate various lines of improvement, both in the chosen statistical methodology (e.g. to adopt a Bayesian framework to control the vast number of copy number parameters) as well in the mathematical modelling of tumor progression. These advances should be developed in tandem with richer and larger data set that are likely to occur with improved genomic technology. Our method (and improvements) can also be applied to SNP array data. Recent methods for SNP array analysis, e.g. [13, 14], distingusih the two possible alleles; this might be useful for providing more accurate inference on copy numbers and the copy number level of the reference population, because each SNP carries two observations and not just one as for CGH arrays.
Methods
Materials
Cell lines with known copy number gains and losses were used to establish a copy number model. Here, we applied several cell lines including trisomy13, trisomy18, trisomy21 and 49, XXXXX. Normal male and female DNA were also used.
Twenty-nine pairs of primary breast tumors and their matched lymph node metastasis were provided by Copenhagen University Hospital. The project was approved by the Scientific and Ethical Committee of the Copenhagen and Frederiksberg Municipalities.
Arrays covering the whole genome with elements produced from bacterial artificial chromosome (BAC) clones were obtained from the Wellcome Trust Sanger Institute. The human DNA fragments of the 3340 BAC clones are spaced at approximately 1 Mb intervals across each chromosome arm. The experimental process is explained in details in [15]. Briefly, each clone is spotted on slides in a neighboring triplicate pattern. Annotations of the clones are based on the 1-Mb clone information published by the Wellcome Trust Sanger Institute and updated using the 38_36 version of the 1-Mb clone information released by Ensembl.
Normalization of arrays
The intensities of Cy3 (tumor sample) and Cy5 (reference) were extracted respectively from 16 bit TIF files using the Tracker (Applied Precision) software. Subsequently data were subjected to quality assessment and a filtering process to remove the clones with poor quality.
Clones were removed from the subsequent analysis if one of the following conditions is fulfilled: a) The spot is labeled "Undetected" by Tracker, b) The Sanger annotation of a clone is inconsistent with the Ensemble annotation (see above), c) The spot's Cy5 (reference) intensity is less than two times the standard deviation (SD) of its background intensity, d) Only one spot out of the three replicates is left after the above procedure, e) The CV of the intensity ratios Cy3/Cy5 for one clone exceeds 0.08, and f) The clone maps to chromosome Y.
Finally, the ratios of Cy3/Cy5 intensities are calculated and log transformed. Subsequently, the median of the log-ratios from the whole array is subtracted from each log-ratio to normalize all spots.
The copy number model
We modeled the Cy3/Cy5 intensity ratios in the following way. Assume that the test sample is homogeneous, i.e. a given clone has the same copy number in all cells in the sample, and that the clones are divided into distinct segments such that all clones in a segment have the same copy number.
where γ is a constant depending on the quality of the DNA in the tube, amplification, scanning and other hybridization and experimental conditions. The error term ε_{ ij }is assumed to have mean zero and common variance, and α is a constant that is justified from calibration experiments [see Additional file 1] and appears to be sample independent (but likely platform specific). The model assumes the variance is proportional to the true ratio of copy numbers in the test and reference samples.
where C_{1R}(C_{0R}) is the copy number of the test (reference) sample corresponding to x_{ R }and ε' is an error term (not equal to ε). The error term is defined such that (1 + ε_{ ij })/(1 + ε_{ R }) = 1 + ${{\u03f5}^{\prime}}_{ij}$. Typically, the majority of clones in a tumor sample have copy number two and we assume C_{1R}= 2. In general, C_{0i}/C_{0R}= 1 in the reference sample, unless the reference sample has only one chromosome X and C_{0i}/C_{0R}= 1/2 for chromosome X clones.
Further, assume
log(z_{ ij }) ~ N(α log(C_{ i }) + β, σ^{2}), (6)
where β is the mean of ${{\u03f5}^{\prime}}_{ij}$ and σ^{2} the variance. Equation (3) ensures the variance is independent of the copy number. If a series of experiments with known copy numbers are available, the parameters in equation (6) can be estimated using linear regression.
In order to determine α and β in equation (6), we used the normal references and the samples with known copy number aberrations. We have data corresponding to the following ratios: 0.5 (46, XY versus 46, XX), 1.5 (47, XX+13 versus the normal reference, and 47, XX+18 versus the normal reference), 2 (chr X, the normal females versus the normal males), and 2.5 (49, XXXXX versus 46, XX).
Mixture modeling of tumor samples
K is the number of subpopulations, p_{ k }is the percentage of the k th subpopulation, Σ_{ k }p_{ k }= 1, and C_{ ik }≥ 0 is the copy number in the k th subpopulation relative to the copy number of the test sample. Normally, the same region in different subpopulations will not experience both gains and losses [16].
Therefore, we restrict our model parameters in the following way. The first subpopulation, with percentage p_{0}, is assumed to be normal; i.e. C_{i 0}= 1 for all clones in this subpopulation. We assume the other subpopulations are derived from each other, such that either
1 = C_{i 0}≤ C_{ ik }≤ C_{i,k+1} (9)
or
1 = C_{i 0}≥ C_{ ik }≥ C_{i,k+1}. (10)
That is, we consider subpopulation k + 1 to be derived from subpopulation k by either A) introducing a new copy number aberration (C_{ ik }= 1, but C_{i,k+1}≠ 1), B) increasing an existing copy number gain, or C) increasing an existing copy number loss.
Estimation of copy numbers and percentages
To estimate the copy numbers and the percentages of the subpopulations, we first divide the clones into segments, such that all clones in a segment have the same copy number profile. To segment the clones, we used DNAcopy [17] implemented in R. A comparison study of several segmentation approaches have been done recently [18], and DNAcopy came out best.
After segmentation, all clones in one segment are assigned the same value, namely the mean of the intensity values in that particular segment. Missing clone values mapping within a segment are given the same value as the segment, while missing clone values located between segments have values imputed using the minimum absolute value of the two flanking segments. The copy number level closest to zero is declared unchanged ("normal level") and corresponds to two copies. In the final step, all segments are normalized by subtracting the value of the normal level.
the mean intensity of segment i.
over p_{ k }, k = 0, ..., K and C_{ ik }with the constraints given in equations (9) and (10). Here ($\widehat{\alpha}$, $\widehat{\beta}$) is obtained from the samples with known copy number alterations and assumed to be known in equation (12).
where m_{ i }is the number of clones in segment i. Equation (13) involves summation over fewer terms than equation (12) and might thus be preferred. For fixed K, there are K - 1 percentage parameters and K - 1 copy numbers for each segment; in total (K - 1) + n(K - 1) = (n + 1)(K - 1) parameters, where n is the number of segments. The number of parameters scales with the number of clones; however, since the copy numbers assume integer values we do not obtain a perfect fit to the log-intensities in equation (12) or (13). To facilitate comparison between different experiments, we use the normalized quantity $NLS=\sqrt{L{S}^{\prime}/n}$, where n is the number of segments in one experiment.
Classification of samples
To classify a sample we go through the following steps. The estimation procedure outlined in the previous section is applied.
Estimation of subpopulation number and parameters
- 1)
Apply DNACopy to obtain a list of segments.
- 2)
Fit K subpopulations to obtain NLS_{ K }, K = 2, 3, 4, with corresponding percentages (p_{0}, p_{1}, ..., p_{ K }) and copy number profiles (C_{i 1}, ..., C_{ iK }). The first subpopulation is supposed to consist of pure normal cells.
Simulation of bootstrap samples
- 3)
Choose α and β according to the estimated normal distributions obtained by linear regression. The distributions are restricted to the 95% CI to avoid extreme values.
- 4)
For fixed K, simulate log-intensity values for each estimated copy number profile, k = 1, ..., K, by adding noise: For a clone with copy number C, compute the mean log-intensity β + αC and add noise according to a normal distribution N(0, ${\widehat{\sigma}}^{2}=\frac{1}{M}{\displaystyle \sum _{ij}{(\mathrm{log}({z}_{ij})-{\widehat{\mu}}_{j})}^{2}}$).
- 5)
Repeat the previous step B times for each sample and each value of K to obtain simulated samples with K = 2, 3 or 4 subpopulations. For each simulated sample fit 2, 3 and 4 subpopulations according to step 1 and 2, and calculate the corresponding NLS_{ bKC }. Here b denotes the b th simulated/bootstrapped sample with K subpopulations, fitted to C subpopulations, C = 2, 3, 4.
Evaluation of NLS_{K} from real samples
- 6)
If NLS_{2} is below the 95 percentile of the empirical distribution of NLS_{b 22}, accept the sample as two populations, otherwise
- 7)
If NLS_{3} is below the 95 percentile of the empirical distribution of NLS_{b 33}, accept the sample as three populations, otherwise
- 8)
Accept the sample as 4 subpopulations.
Simulation
To test the classifier we choose some of the simulated samples and used these as input to the bootstrap procedure described above. For each real sample we choose four simulated samples as input and compared the result to the known input.
We also tested how robust the classifier is to deviations from the assumption of sequential tumor evolution. This we did by adding or subtracting a Poisson number of copies to the original copy number. For each segment, S_{ i }X_{ i }copies were added to the original copy number in subpopulation i. Here, P(S_{ i }= 1) = P(S_{ i }= 1) = 0.5 and X_{ i }is Poisson(λ). If the copy number fell below 0, it was put to zero. The parameter λ was varied over λ = 0.25, 0.5 and 1. For each real sample with K = 3 estimated subpopulations we simulated 2 samples (in total 2·23 = 46 simulated samples) in this way, and for each real sample with K = 4 we simulated 4 samples (in total 4·10 = 40 simulated samples).
Declarations
Acknowledgements
KW has been supported by the PhD-school for Industrial-related Molecular Biology at Aarhus University. CW is supported by the Danish Cancer Society. The work has been financed by the Danish Platform for Integrative Biology of the National Research Foundation, the will of Edith Stern and the "Race Against Breast Cancer".
Authors’ Affiliations
References
- Dexter D, Leith J: Tumour heterogeneity and drug resistance. J Clin Oncol. 1986, 4 (2): 244-257.PubMedGoogle Scholar
- Heppner G, Yamashina K, Miller B, Miller F: Tumour heterogeneity in metastasis. Prog Clin Biol Res. 1986, 212: 45-59.PubMedGoogle Scholar
- Heppner G: Tumour heterogeneity. Cancer Res. 1984, 44 (6): 2259-2265.PubMedGoogle Scholar
- Black D: The genetics of breast cancer. Eur J Cancer. 1994, 30A (13): 1957-1961. 10.1016/0959-8049(94)00386-J.View ArticlePubMedGoogle Scholar
- Devilee P, Cornelisse C: Somatic genetic changes in human breast cancer. Biochim Biophys Acta. 1994, 1198 (2–3): 113-130.PubMedGoogle Scholar
- el Ashry D, Lippman M: Molecular biology of breast carcinoma. World J Surg. 1994, 18: 12-20. 10.1007/BF00348187.View ArticlePubMedGoogle Scholar
- Ford D, Easton D: The genetics of breast and ovarian cancer. Br J Cancer. 1995, 72 (4): 805-812. 10.1038/bjc.1995.417.PubMed CentralView ArticlePubMedGoogle Scholar
- O'Connell P, Pekkel V, Fuqua S, Osborne C, Allred D: Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat. 1994, 32: 5-12. 10.1007/BF00666201.View ArticlePubMedGoogle Scholar
- Andersen CL, Wiuf C, Kruhoffer M, Korsgaard M, Laurberg S, Orntoft TF: Frequent occurrence of uniparental disomy in colorectal cancer. Carcinogenesis. 2007, 28: 38-48. 10.1093/carcin/bgl086.View ArticlePubMedGoogle Scholar
- Aubele M, Mattis A, Zitzelsberger H, Walch A, Kremer M, Hutzler P, Hofler H, Werner M: Intratumoural heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization. Cancer Genet Cytogenet. 1999, 110 (2): 94-102. 10.1016/S0165-4608(98)00205-2.View ArticlePubMedGoogle Scholar
- Khan MZ, Haleem A, Hassani HA, Kfoury H: Cytopathological grading, as a predictor of histopathological grade, in ductal carcinoma (NOS) of breast, on air-dried Diff-Quik smears. Diagn Cytopathol. 2003, 29 (4): 185-93. 10.1002/dc.10285.View ArticlePubMedGoogle Scholar
- Fridlyand J, Snijders AM, Pinkel D, Albertson DG, Jain ANAN: Hidden Markov models approach to the analysis of array CGH data. Journal of Multivariate Analysis. 2004, 90: 132-153. 10.1016/j.jmva.2004.02.008.View ArticleGoogle Scholar
- Lamy P, Andersen C, Dyrskjot L, Torring N, Wiuf C: A Hidden Markov Model to estimate population mixture and allelic copy-numbers in cancers using Affymetrix SNP arrays. BMC Bioinformatics. 2007Google Scholar
- LaFramboise T, Weir BA, Zhao X, Beroukhim R, Li C, Harrington D, Sellers WR, Meyerson M: Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol. 2005, 1 (6): e65-10.1371/journal.pcbi.0010065.PubMed CentralView ArticlePubMedGoogle Scholar
- Li J, Gromov P, Gromova I, Moreira J, Timmermans-Wielenga V, Rank F, Wang K, Li S, Li H, Wiuf C, Yang H, Zhang X, Bolund L, Celis J: Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis. Proteomics. 2008, 8 (23-24): 5038-5052. 10.1002/pmic.200800303.View ArticlePubMedGoogle Scholar
- Lips EH, van Eijk R, de Graaf EJR, Doornebosch PG, de Miranda NFCC, Oosting J, Karsten T, Eilers PHC, Tollenaar RAEM, van Wezel T, Morreau H: Progression and tumor heterogeneity analysis in early rectal cancer. Clin Cancer Res. 2008, 14 (3): 772-81. 10.1158/1078-0432.CCR-07-2052.View ArticlePubMedGoogle Scholar
- Olshen AB, Venkatraman ES: Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004, 5 (4): 557-572. 10.1093/biostatistics/kxh008.View ArticlePubMedGoogle Scholar
- Willenbrock H, Fridlyand J: A Comparison Study: Applying Segmentation to Array CGH Data for Downstream Analyses. Bioinformatics. 2005, 21 (22): 4084-4091. 10.1093/bioinformatics/bti677.View ArticlePubMedGoogle Scholar
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.